Study S003350

A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Influence of HDM1005 on Gastric Emptying and Drug-Drug Interaction of HDM1005 and Metformin, Atorvastatin, Warfarin, and Digoxin in Overweight/Obese Adult Chinese Subjects

ClinicalTrials.gov record

Registration

Registration: NCT07502001
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 42
Start: 2026-04-08
Primary completion: 2026-12-01
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Overweight; Obesity
Interventions: DRUG:Acetaminophen; DRUG:Metformin; DRUG:Warfarin; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:HDM1005 injection
Results posted: FALSE

Registered primary outcomes

Area Under the Concentration Time Curve From Time Zero to ∞ [ AUC(0- ∞)] [Up to Day 115]
Maximum observed concentration (Cmax) [Up to Day 115]
Area Under the Concentration Time Curve From Time Zero to t [ AUC(0- t)] [Up to Day 115]
Time of maximum observed concentration (Tmax) [Up to Day 115]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.